Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001171843-25-001717
Filing Date
2025-03-26
Accepted
2025-03-26 11:01:26
Documents
10
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K f6k_032625.htm 6-K 6616
2 EXHIBIT 99.1 exh_991.htm EX-99.1 560151
3 EXHIBIT 99.2 exh_992.htm EX-99.2 329059
4 GRAPHIC logo.jpg GRAPHIC 10335
5 GRAPHIC logo_small.jpg GRAPHIC 6393
6 GRAPHIC davidsonhdr.jpg GRAPHIC 11777
7 GRAPHIC davidsonftr.jpg GRAPHIC 14095
8 GRAPHIC smythelogo.jpg GRAPHIC 6389
9 GRAPHIC smytheftr.jpg GRAPHIC 21468
10 GRAPHIC smythesig.jpg GRAPHIC 2275
  Complete submission text file 0001171843-25-001717.txt   998019
Mailing Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5
Business Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5 403-607-2621
XORTX Therapeutics Inc. (Filer) CIK: 0001729214 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40858 | Film No.: 25770727
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)